Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547651 · ClinicalTrials.gov registry record · Phase 3
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 637
- Enrollment target
NCT00547651 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 637 participants.
The verdict
NCT00547651, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 637 participants
- Enrollment target
Study Summary
This study drug (Amrubicin) is believed to work by stopping the tumor cells in your body from growing. The purpose of this study is to evaluate the effect of amrubicin compared to topotecan in the treatment of small cell lung cancer.
Interventions
- DRUG Topotecan
- DRUG Amrubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 637 participants |
| Start Date | 2007-09-01 |
| Est. Completion | 2011-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547651
The ClinicalTrials.gov registry entry for NCT00547651 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 637 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT00547651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547651 about?
NCT00547651 is a clinical study titled "AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy". This study drug (Amrubicin) is believed to work by stopping the tumor cells in your body from growing. The purpose of this study is to evaluate the effect of amrubicin compared to topotecan in the treatment of small cell lung cancer.
What is the current status of trial NCT00547651?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 637 participants. The study started on 2007-09-01. Estimated completion is 2011-05-01.
What interventions are being tested in trial NCT00547651?
The interventions under investigation include: Topotecan (DRUG), Amrubicin (DRUG).
Who is sponsoring clinical trial NCT00547651?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.